JP2016539164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539164A5 JP2016539164A5 JP2016536659A JP2016536659A JP2016539164A5 JP 2016539164 A5 JP2016539164 A5 JP 2016539164A5 JP 2016536659 A JP2016536659 A JP 2016536659A JP 2016536659 A JP2016536659 A JP 2016536659A JP 2016539164 A5 JP2016539164 A5 JP 2016539164A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutically acceptable
- acceptable salt
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 12
- 238000013268 sustained release Methods 0.000 claims 11
- 239000012730 sustained-release form Substances 0.000 claims 11
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 8
- 229960003086 naltrexone Drugs 0.000 claims 8
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 7
- 229960001058 bupropion Drugs 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 208000006011 Stroke Diseases 0.000 claims 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 230000002411 adverse Effects 0.000 claims 3
- 230000007211 cardiovascular event Effects 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 230000000250 revascularization Effects 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010014486 Elevated triglycerides Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 claims 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- 206010047302 ventricular tachycardia Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913216P | 2013-12-06 | 2013-12-06 | |
| US61/913,216 | 2013-12-06 | ||
| US201361914938P | 2013-12-11 | 2013-12-11 | |
| US61/914,938 | 2013-12-11 | ||
| US201461984580P | 2014-04-25 | 2014-04-25 | |
| US61/984,580 | 2014-04-25 | ||
| US14/322,810 US8969371B1 (en) | 2013-12-06 | 2014-07-02 | Compositions and methods for weight loss in at risk patient populations |
| US14/322,810 | 2014-07-02 | ||
| PCT/US2014/068527 WO2015085044A1 (en) | 2013-12-06 | 2014-12-04 | Compositions and methods for reducing major adverse cardiovascular events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220444A Division JP7204634B2 (ja) | 2013-12-06 | 2019-12-05 | 主要有害心血管事象を低減するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539164A JP2016539164A (ja) | 2016-12-15 |
| JP2016539164A5 true JP2016539164A5 (cg-RX-API-DMAC7.html) | 2018-01-18 |
| JP6665094B2 JP6665094B2 (ja) | 2020-03-13 |
Family
ID=52575014
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536659A Active JP6665094B2 (ja) | 2013-12-06 | 2014-12-04 | 主要有害心血管事象を低減するための組成物及び方法 |
| JP2019220444A Active JP7204634B2 (ja) | 2013-12-06 | 2019-12-05 | 主要有害心血管事象を低減するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220444A Active JP7204634B2 (ja) | 2013-12-06 | 2019-12-05 | 主要有害心血管事象を低減するための組成物及び方法 |
Country Status (33)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE388698T1 (de) | 2003-04-29 | 2008-03-15 | Orexigen Therapeutics Inc | Zusammensetzungen zur beeinflussung des gewichtsverlusts |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| WO2008060964A2 (en) | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| JP6196041B2 (ja) | 2010-01-11 | 2017-09-13 | オレキシジェン・セラピューティクス・インコーポレーテッド | 大うつ病を有する患者において減量療法を提供する方法 |
| PE20150358A1 (es) * | 2012-06-06 | 2015-04-06 | Orexigen Therapeutics Inc | Metodos para el tratamiento del sobrepeso y de la obesidad |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| EP3493574B1 (en) * | 2016-08-11 | 2023-04-12 | Huawei Technologies Co., Ltd. | Wireless communication method based on unlicensed frequency spectrum, and base station and terminal device |
| US20250332152A1 (en) * | 2021-12-09 | 2025-10-30 | Incarda Therapeutics, Inc. | Inhaled therapy for cardiac arrhythmia |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217353A (en) | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
| IL58649A (en) | 1978-11-10 | 1982-04-30 | Beecham Group Ltd | Pharmaceutical dispensing container |
| DE3381877D1 (de) | 1982-03-16 | 1990-10-18 | Univ Rockefeller | Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen. |
| GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| ES2058272T3 (es) | 1987-05-04 | 1994-11-01 | Lilly Co Eli | Fluoxetina util para el tratamiento de la diabetes. |
| US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
| US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
| DE4136215A1 (de) | 1991-11-02 | 1993-05-06 | Ferring Arzneimittel Gmbh, 2300 Kiel, De | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie |
| US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| EP0782445B1 (en) | 1994-09-19 | 2002-03-13 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
| US5627187A (en) | 1995-04-12 | 1997-05-06 | Katz; Bruce E. | 5-FU for treating actinic kerotoses |
| GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| US5716976A (en) | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| JPH11505547A (ja) | 1996-03-13 | 1999-05-21 | エール ユニバーシティ | ナルトレキソン及び関連化合物を用いる禁煙処置 |
| ATE344668T1 (de) | 1996-05-07 | 2006-11-15 | Pliva Istrazivanje I Razvoj D | Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus |
| IL127715A (en) | 1996-06-28 | 2004-07-25 | Ortho Mcneil Pharm Inc | Anticonvulsant sulfamate derivatives useful in treating obesity |
| US5878750A (en) | 1996-11-14 | 1999-03-09 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
| KR20010030860A (ko) | 1997-10-03 | 2001-04-16 | 캐리 메디컬 코퍼레이션 | 니코틴 리셉터 길항제, 및 항-진정제 또는 항-불안 약물을함유하는 니코틴 중독치료용 조성물 |
| US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
| EP1051167A1 (en) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-) -bupropion |
| US6048322A (en) | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
| US6589553B2 (en) | 2001-02-08 | 2003-07-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral dosage form |
| US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
| NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
| US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
| JP2003509349A (ja) | 1999-09-15 | 2003-03-11 | エラン ファーマシューティカルズ，インコーポレイテッド | ヘテロアリールメタンスルホンアミドを使用するニューロパシー性疼痛を処置するための方法。 |
| US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
| GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
| WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
| CA2397726A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
| CN101703777B (zh) | 2000-02-08 | 2012-11-28 | 欧罗赛铁克股份有限公司 | 抗破坏口服阿片样激动剂 |
| US6306436B1 (en) | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| ES2310192T3 (es) | 2000-09-18 | 2009-01-01 | Sanos Bioscience A/S | Uso de peptidos glp-2. |
| JP2004534056A (ja) | 2001-06-08 | 2004-11-11 | エンドー ファーマシューティカルズ， インコーポレイティド | アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス |
| US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| EP1414418A1 (en) | 2001-08-06 | 2004-05-06 | Euro-Celtique S.A. | Compositions and methods to prevent abuse of opioids |
| US7914818B2 (en) | 2001-08-06 | 2011-03-29 | Purdue Pharma L.P. | Opioid agonist formulations with releasable and sequestered antagonist |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
| US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
| US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
| BR0309969A (pt) | 2002-05-17 | 2005-04-26 | Merck Patent Gmbh | Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos |
| KR20110043664A (ko) | 2002-05-17 | 2011-04-27 | 듀크 유니버시티 | 비만치료방법 |
| US20040005368A1 (en) | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
| US6972291B2 (en) | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
| US7086532B2 (en) | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
| US7273884B2 (en) | 2002-09-13 | 2007-09-25 | Eisai, Inc. | Method of treating tremors |
| WO2004071423A2 (en) | 2003-02-05 | 2004-08-26 | Euro-Celtique S.A. | Methods of administering opioid antagonists and compositions thereof |
| WO2004078113A2 (en) | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
| WO2004091593A2 (en) | 2003-04-14 | 2004-10-28 | Pain Therapeutics, Inc. | Methods for the treatment of pain comprising opioid antagonists |
| ATE388698T1 (de) | 2003-04-29 | 2008-03-15 | Orexigen Therapeutics Inc | Zusammensetzungen zur beeinflussung des gewichtsverlusts |
| BRPI0410271A (pt) | 2003-05-16 | 2006-05-16 | Pfizer Prod Inc | combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas |
| EP1635832A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
| HRP20100368T1 (hr) | 2003-09-25 | 2010-08-31 | Euro-Celtique S.A. | Farmaceutske kombinacije hidrokodona i naltreksona |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
| BRPI0506829A (pt) | 2004-01-13 | 2007-05-29 | Univ Duke | composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso |
| US20050245541A1 (en) | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
| BRPI0510593A (pt) | 2004-05-03 | 2007-11-20 | Univ Duke | composições para afetar a perda de peso |
| US20050250838A1 (en) | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
| CN101001619A (zh) | 2004-08-03 | 2007-07-18 | 奥雷西根治疗公司 | 影响体重减轻的安非他酮和第二化合物的组合物 |
| WO2007047351A2 (en) | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
| US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| AR058239A1 (es) | 2005-11-28 | 2008-01-23 | Orexigen Therapeutics Inc | Metodos para tratar trastornos de ansiedad |
| EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
| JP5478245B2 (ja) | 2006-06-05 | 2014-04-23 | オレキシジェン・セラピューティクス・インコーポレーテッド | ナルトレキソンの徐放型配合物 |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| KR20150029762A (ko) | 2006-06-19 | 2015-03-18 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
| WO2008011150A1 (en) | 2006-07-20 | 2008-01-24 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
| US8682445B2 (en) | 2006-07-28 | 2014-03-25 | Cyberonics, Inc. | Patient management system for treating depression using an implantable medical device |
| US8088786B2 (en) | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
| WO2008060964A2 (en) | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| GB2447949B (en) | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
| WO2009035473A2 (en) | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| JP6196041B2 (ja) * | 2010-01-11 | 2017-09-13 | オレキシジェン・セラピューティクス・インコーポレーテッド | 大うつ病を有する患者において減量療法を提供する方法 |
| WO2012075453A1 (en) | 2010-12-03 | 2012-06-07 | Orexigen Therapeutics, Inc. | Methods for reducing binge or compulsive eating |
| PE20150358A1 (es) | 2012-06-06 | 2015-04-06 | Orexigen Therapeutics Inc | Metodos para el tratamiento del sobrepeso y de la obesidad |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
-
2014
- 2014-07-02 US US14/322,810 patent/US8969371B1/en active Active
- 2014-12-03 JO JOP/2014/0344A patent/JOP20140344B1/ar active
- 2014-12-04 PE PE2016000724A patent/PE20161034A1/es unknown
- 2014-12-04 US US15/101,878 patent/US10231962B2/en active Active
- 2014-12-04 CA CA2932127A patent/CA2932127C/en active Active
- 2014-12-04 HU HUE14867191A patent/HUE057551T2/hu unknown
- 2014-12-04 WO PCT/US2014/068527 patent/WO2015085044A1/en not_active Ceased
- 2014-12-04 CN CN202310405573.1A patent/CN117159547A/zh active Pending
- 2014-12-04 EP EP21202875.7A patent/EP4005571A1/en active Pending
- 2014-12-04 SG SG10201808055QA patent/SG10201808055QA/en unknown
- 2014-12-04 PT PT148671910T patent/PT3076971T/pt unknown
- 2014-12-04 CN CN202111066895.5A patent/CN114404419A/zh active Pending
- 2014-12-04 JP JP2016536659A patent/JP6665094B2/ja active Active
- 2014-12-04 ES ES14867191T patent/ES2903391T3/es active Active
- 2014-12-04 RS RS20220039A patent/RS62846B1/sr unknown
- 2014-12-04 SI SI201431935T patent/SI3076971T1/sl unknown
- 2014-12-04 PL PL14867191T patent/PL3076971T3/pl unknown
- 2014-12-04 UY UY0001035864A patent/UY35864A/es not_active Application Discontinuation
- 2014-12-04 EA EA201690964A patent/EA201690964A1/ru unknown
- 2014-12-04 DK DK14867191.0T patent/DK3076971T3/da active
- 2014-12-04 KR KR1020237036479A patent/KR20230152800A/ko active Pending
- 2014-12-04 IL IL300870A patent/IL300870A/en unknown
- 2014-12-04 LT LTEPPCT/US2014/068527T patent/LT3076971T/lt unknown
- 2014-12-04 BR BR112016012755A patent/BR112016012755A2/pt not_active Application Discontinuation
- 2014-12-04 AU AU2014360492A patent/AU2014360492A1/en not_active Abandoned
- 2014-12-04 HR HRP20220058TT patent/HRP20220058T1/hr unknown
- 2014-12-04 EP EP14867191.0A patent/EP3076971B1/en active Active
- 2014-12-04 RU RU2016122483A patent/RU2711638C2/ru active
- 2014-12-04 MX MX2016007231A patent/MX389742B/es unknown
- 2014-12-04 KR KR1020167017977A patent/KR102472432B1/ko active Active
- 2014-12-04 CR CR20160313A patent/CR20160313A/es unknown
- 2014-12-04 KR KR1020227041333A patent/KR20220165791A/ko not_active Ceased
- 2014-12-04 TN TN2016000231A patent/TN2016000231A1/en unknown
- 2014-12-04 CN CN201480072729.8A patent/CN105899210A/zh active Pending
- 2014-12-05 TW TW103142498A patent/TWI661826B/zh active
-
2015
- 2015-03-02 US US14/635,518 patent/US9119850B2/en active Active
- 2015-08-28 US US14/839,792 patent/US9801875B2/en active Active
-
2016
- 2016-05-30 IL IL245919A patent/IL245919A0/en unknown
- 2016-06-02 MX MX2022001251A patent/MX2022001251A/es unknown
- 2016-06-03 CL CL2016001362A patent/CL2016001362A1/es unknown
- 2016-06-06 ZA ZA2016/03831A patent/ZA201603831B/en unknown
- 2016-07-04 EC ECIEPI201657765A patent/ECSP16057765A/es unknown
-
2017
- 2017-10-05 US US15/725,830 patent/US10231964B2/en active Active
-
2019
- 2019-03-18 US US16/356,657 patent/US10828294B2/en active Active
- 2019-03-18 US US16/356,663 patent/US10835527B2/en active Active
- 2019-12-05 JP JP2019220444A patent/JP7204634B2/ja active Active
-
2020
- 2020-11-16 US US17/099,316 patent/US11998542B2/en active Active
-
2021
- 2021-04-07 IL IL282117A patent/IL282117A/en unknown
-
2022
- 2022-01-19 CY CY20221100048T patent/CY1125114T1/el unknown
-
2024
- 2024-06-03 US US18/731,965 patent/US20250144089A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539164A5 (cg-RX-API-DMAC7.html) | ||
| HRP20220058T1 (hr) | Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja | |
| JP2022062151A5 (cg-RX-API-DMAC7.html) | ||
| Stiell et al. | A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm | |
| JP6356684B2 (ja) | コルヒチン誘導体の投与による心血管イベントの処置または予防 | |
| Conde et al. | Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation | |
| EP2300001A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
| JP2019206562A5 (cg-RX-API-DMAC7.html) | ||
| Onk et al. | Is the preoperative administration of amiodarone or metoprolol more effective in reducing atrial fibrillation: after coronary bypass surgery? | |
| HRP20250931T1 (hr) | Pripravak za upotrebu u postupku liječenja prekomjerne težine i pretilosti kod pacijenata s visokim kardiovaskularnim rizikom | |
| Crijns | Rate versus rhythm control in patients with atrial fibrillation: what the trials really say | |
| Quah et al. | The management of the older adult patient with anomalous left coronary artery from the pulmonary artery syndrome: a presentation of two cases and review of the literature | |
| Codolosa et al. | Update on ranolazine in the management of angina | |
| JP2019514925A5 (cg-RX-API-DMAC7.html) | ||
| Boriani et al. | The effects of gender on electrical therapies for the heart: physiology, epidemiology, and access to therapies | |
| Takahiro et al. | Accidental hypothermia-induced electrical storm successfully treated with isoproterenol | |
| Camm et al. | Medical treatment of atrial fibrillation | |
| Vora et al. | Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study | |
| Demangone | ECG manifestations: noncoronary heart disease | |
| JP2020523408A5 (cg-RX-API-DMAC7.html) | ||
| Selvaraj et al. | Effect of single intraoperative dose of amiodarone in patients with rheumatic valvular heart disease and atrial fibrillation undergoing valve replacement surgery | |
| Duggan et al. | Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation | |
| Efthimiadis et al. | Hypertrophic cardiomyopathy associated with an anomalous origin of right coronary artery: case report and review of the literature | |
| Breithardt et al. | Acute effects of resynchronisation treatment on functional mitral regurgitation in dilated cardiomyopathy | |
| Yavuz et al. | Role of endogenous adenosine in atrial fibrillation after coronary artery bypass graft |